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sugar level was observed in 20 patients, but no other side 
effects had appeared.
Conclusions Pleurodesis with 50 % glucose is an easy, 
safe, and effective treatment modality. It is therefore con-
sidered to be a useful alternative method for pleurodesis.
Keywords Pleurodesis · Lung resection · Pneumothorax · 
Postoperative care · 50 % Glucose solution
Introduction
Pleurodesis is commonly performed for patients with pul-
monary air leakage after lung resection and for those who 
should avoid surgery [1–5]. Various methods using vari-
ous preparations have been reported; OK-432 is most often 
used for pleurodesis in Japan, and talc is used in Western 
countries. Although several studies have reported the effi-
cacy and the safety of talc, its use had not been approved in 
Japan, as there have also been cases of talc that contained 
asbestos. However, only for patients with malignant pleural 
effusions, the use of purified talc was approved in Decem-
ber 2013 in Japan; however, OK-432 has been primarily 
used for postoperative air leakage and pneumothorax [6–9]. 
Pleurodesis using OK-432 is currently the most commonly 
performed technique at our hospital as well. These methods 
aim for adhesion through an inflammatory reaction caused 
by pleural stimulation instilled by the preparations [10, 11]. 
Chemical pleurodesis occasionally causes marked discom-
fort in patients, such as severe chest pain and a fever, and 
there are several reports of severe complications [12–14]. 
Therefore, it is necessary to develop safer agents for the 
treatment of pleurodesis. Therefore, we actively perform 
pleurodesis at our hospital using a 50 % glucose solution, 
which has no medical properties, has few side effects, 
Abstract 
Purpose Pleurodesis is performed in patients demonstrat-
ing air leakage after lung resection and in those with pneu-
mothorax who must avoid surgery. However, there have so 
far been very few reports of pleurodesis with 50 % glucose. 
We herein examined the feasibility and effectiveness of this 
novel pleurodesis technique.
Methods Thirty-five patients after lung resection and 11 
pneumothorax patients without surgery were treated with 
pleurodesis using 50 % glucose. Approximately, 200 mL of 
50 % glucose solution was injected into the pleural space 
and repeated until the air leakage stopped. Cases in which 
the air leakage did not stop after three injections were con-
sidered to be unsuccessful and subsequently treated with 
conventional pleurodesis using OK-432.
Results Thirty-nine patients were successfully treated 
with 50 % glucose, although 7 patients required further 
treatment with OK-432. The unsuccessful group had some 
pulmonary comorbidities (P < 0.001), and the pleural effu-
sion volume after pleurodesis was less than that in the suc-
cessful group (P < 0.001). Although the air leakage did not 
stop in unsuccessful patients, the amount of air leakage 
markedly decreased. A temporary elevation of the blood 
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is low cost, and is an easy procedure. Since large clini-
cal trials have not been conducted for pleurodesis using 
a highly concentrated glucose solution, its effectiveness 
and side effects remain unclear. Although there have been 
several reports of the effectiveness of pleurodesis using a 
hypertonic glucose solution for secondary pneumothorax 
or chylothorax [15–17], this is the first report of the use 
of this procedure for all possible indications for pleurode-
sis, including postoperative air leakage after surgery and 
pneumothorax. In this study, the clinical characteristics of 
patients who underwent pleurodesis using 50 % glucose 
solution at our hospital and its effectiveness were evaluated.
Materials and methods
The patients’ background characteristics, clinical condi-
tion, time to drain withdrawal, and side effects were exam-
ined in a total of 46 patients, 35 postoperative patients 
who underwent pleurodesis due to air leakage after lung 
resection, and 11 pneumothorax patients who underwent 
pleurodesis without undergoing surgery, from April 2012 
to March 2014. During this period, although 53 patients 
had to undergo pleurodesis, 7 with diabetes mellitus were 
excluded, since highly concentrated glucose solution 
administered in the pleural space may cause an increase 
in the blood sugar level. Pleurodesis was indicated for the 
treatment of patients who were found to have air leakage 
with a chest tube under a water seal on the third postop-
erative or drainage day. In the conventional method, we 
conducted pleurodesis with OK-432 after the seventh post-
operative day. In the present study, we performed pleurode-
sis with a 50 % glucose solution on the third postoperative 
day for the purpose of earlier removal of the chest tube. 
Because the intra-thoracic administration of highly concen-
trated glucose solution is not currently approved in Japan, 
patients who agreed to this method were included after 
obtaining their informed consent and approval from the 
Institutional Review Board of National Hospital Organiza-
tion Minamikyushu Hospital.
Pleurodesis
Local anesthesia of the parietal pleura was achieved by 
the injection of 10 mL of 1 % lidocaine into the pleural 
space, after which 200 mL of a 50 % glucose solution were 
injected. The chest tube was clamped for 2 h; however, in 
cases with a large air leakage, the tube was connected by a 
water seal and placed in a position higher than the patient’s 
body. During this period, the patients were asked to change 
their position on the bed every 15 min. Two hours after 
administration, the chest tube was opened and left on 
water seal, and the pleural effusion was thus drained. The 
drainage volume was measured every 2 h, and the blood 
sugar levels were measured after the first hour and then 
again 3 and 6 h later. Eating was prohibited 3 h before and 
after administration. Cases in which the air leakage did 
not stop were re-administered the 50 % glucose solution, 
and after three injections of the 50 % glucose solution the 
cases were considered to be unsuccessful and subsequently 
treated with conventional pleurodesis using OK-432.
Statistical analyses
The SPSS ver18 software program (SPSS Inc, Chicago, IL, 
USA) was used for statistical analyses. The drainage vol-
ume data were assessed using the Mann–Whitney U test. 
Other data were evaluated by Fisher’s exact test. A P value 
less than 0.05 was considered to be statistically significant.
Results
The characteristics and results of the 46 patients, who had 
a mean age of 69 years (range 17–86 years), are shown in 
Table 1. There were 39 patients in the successful group 
and 7 in the unsuccessful group. The 7 unsuccessful 
patients had more pulmonary comorbidities than those 
in the successful group (P < 0.001). All of the patients 
who did not have pulmonary comorbidities and 14 of 21 
Table 1  Patients’ characteristics
Total Successful Unsuccessful P value
Number of patients 46 39 7
Sex
 Males 31 24 7 0.078
 Females 15 15 0
Operative diagnosis
 Lung cancer 29 24 5 1.000
 Interstitial lung disease 4 3 1 0.496
 Pneumothorax 13 12 1 0.654
Operation
 Lobectomy 25 21 4 1.000
 Segmentectomy 1 0 1 0.152
 Partial resection 9 7 2 0.609
 Chest drainage 11 11 0 0.171
Comorbidity
 None 25 25 0 <0.001
 Present 21 14 7
  Emphysema 11 8 3 0.33
  Interstitial lung  
disease
5 4 1 1.000
  Emphysema + inter-
stitial lung disease
5 2 3 0.0199
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patients who had pulmonary comorbidities were success-
fully treated with the 50 % glucose solution. Although 
the air leakage did not stop in the unsuccessful patients, 
the amount of air leakage markedly decreased. The 7 
unsuccessful patients were then treated with conven-
tional pleurodesis using 5 KE of OK-432, and the drain 
was removed. The mean frequency for administering the 
50 % glucose solution was 1.4 times (range 1–3 times) in 
the successful group (Table 2). The mean of the drainage 
period was 6.8 days (range 4–8 days) in the successful 
group and 11.3 days (range 8–14 days) in the unsuccess-
ful group. After opening of the drain, a large amount of 
drainage was observed. The drainage volume was signifi-
cantly greater in the successful group than in the unsuc-
cessful group (P < 0.001, Table 3). The patient with the 
largest amount of drainage drained 780 mL in the first 
2 h; however, no hemodynamic deterioration or symptoms 
of dehydration occurred in any patient. The blood sugar 
levels are shown in Table 4. The blood sugar levels of 20 
patients 1 h after injection were greater than 250 mg/dL. 
Although the patients were permitted a meal 3 h after the 
injection, the blood sugar level was below 250 mg/dL in 
all patients after 6 h. All patients were given NSAIDs pro-
phylactically; however, additional doses of analgesic were 
required in 9 patients due to chest pain after administra-
tion of the glucose solution. However, the pain was tem-
porary and not prolonged. Meanwhile, 6 patients in the 
unsuccessful group had a fever of at least 38 °C, and 5 
patients in this group had prolonged severe chest pain for 
more than 3 days after the injection of OK-432. No other 
side effects were observed even in 10 patients with inter-
stitial pneumonia or 6 elderly patients more than 80 years 
of age.
Discussion
There have been very few reports on pleurodesis with a 
50 % glucose solution, and no large clinical study has 
been previously conducted. In addition, the mechanism of 
pleurodesis with a 50 % glucose solution has not yet been 
clarified. In the present study, the pleural effusion volume 
after pleurodesis was significantly greater in the success-
ful group. Thus, it can be inferred that a hypertonic glucose 
solution causes osmotic cell injury and inflammation when 
pleural cells are damaged by the osmotic pressure differ-
ence, thereby inducing the precipitation of fibrin, which 
completes the pleural adhesion. We are currently confirm-
ing the details of this mechanism using experimental ani-
mal models.
Regarding the side effects, a fever was not detected, and 
chest pain was only present at the time of injection; the pain 
was relieved within a few hours and was not prolonged. On 
the other hand, in more than 70 % of patients with failure 
due to air leakage who required OK-432, a fever of at least 
38 °C was noted, and severe chest pain persisted for more 
than 3 days. The stimulation of pleural cells and the inflam-
matory reaction of 50 % glucose as an adhesive drug may 
be milder compared with OK-432; however, 39 patients 
were successfully treated with this method. Thus, several 
patients with air leakage could be treated with this method 
before considering the use of exogenous chemicals.
As a specific side effect of using a 50 % glucose solu-
tion, the temporal elevation of the blood sugar level was 
observed in 20 of 46 cases; however, the levels of all 
patients were less than 250 mg/dL after 6 h. Because a high 
blood sugar level was observed after pleurodesis even in 
non-diabetic patients, diabetic patients should probably not 
undergo this procedure. A rapid induction of pleural effu-
sion was observed, with a peak at 2–4 h after opening of 
the drain; therefore, we carefully monitored the circulatory 
dynamics of all patients. No patients developed dehydra-
tion or blood pressure fluctuations. Because the patients 
were free to drink while performing the procedure, the 
side effects of massive pleural effusion might be minimal. 
Regarding cost, a 50 % glucose solution is clearly reason-
able compared with other drugs and easily obtainable in 
Table 2  The frequency of administration of the 50 % glucose solu-
tion
Successful Unsuccessful
One time 28 0
Two times 8 0
Three times 3 7
Table 3  The mean drainage volume after pleurodesis
Successful Unsuccessful P value
Two hours 372.6 175.9 0.001
Four hours 153.9 66.9 0.004
Six hours 58.5 38.8 0.572
Eight hours 20.8 15.6 0.345
Total volume (mL) 605.7 297.2 <0.001
Table 4  Blood sugar levels after pleurodesis
BSL blood sugar level
BSL (mg/dL) One hour Three hours Six hours
≤180 12 36 45
181–250 14 8 1
251–350 16 2 0
≥351 4 0 0
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daily medical practice. In addition, the risk of infection is 
thought to be low, considering that it is a sterilized intrave-
nous fluid preparation and hypertonic glucose solution.
In summary, we successfully treated 39 of 46 patients 
with air leakage by pleurodesis with a 50 % glucose solu-
tion. This method appears to be an easy, safe, effective, 
and low-cost treatment. A 50 % glucose solution does not 
include exogenous toxic chemical substances; thus, it could 
be considered to be an alternative method of pleurodesis 
before conducting conventional chemical pleurodesis.
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